A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Ansun Biopharma, Inc.
ClinicalTrials.gov Identifier:
NCT01644877
First received: July 17, 2012
Last updated: August 2, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)